Fox Chase Cancer Center News

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant chemoimmunotherapy can be considered in select patients.

Fox Chase Cancer Center researchers found that combining an imaging exam with a particular blood test can help identify which patients still have cancer in their bladder after treatment and which may be cancer-free.

Researchers and clinical nurse researchers at Fox Chase Cancer Center created a program to help kidney cancer patients better understand and feel more comfortable with clinical trials. One goal is to increase diversity in clinical trial enrollment.

By aligning treatment with patients’ values and goals, Fox Chase Cancer Center clinicians are infusing Goal Concordant Care into routine practice, partnering with their patients to honor what matters most when facing serious illness.

Discoveries from Siddharth Balachandran, PhD, reveal how the same immune pathways that fight viruses can be harnessed to make cancer immunotherapy more effective, highlighting the transformative power of basic science.

Khariton joins Fox Chase during a period of sustained growth and integration of its clinical services and research enterprise across Temple Health, the Lewis Katz School of Medicine and Temple University.

Fox Chase was ranked at or above the 95th percentile for the honor, which highlights how employee and physician engagement strengthen research excellence and patient care.

SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, enters a strategic partnership with Fox Chase Cancer Center.